Patents Assigned to XSPRAY PHARMA AB
  • Pharmaceutical compositions
    Patent number: 11963951
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: April 23, 2024
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240024248
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Application
    Filed: July 27, 2023
    Publication date: January 25, 2024
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Thomas MEIJER, Victor SÖDERBERG
  • Rapidly disintegrating solid oral dosage forms containing dasatinib
    Patent number: 11833249
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: December 5, 2023
    Assignee: XSPRAY PHARMA AB
    Inventors: Per Andersson, Thomas Meijer, Victor Söderberg
  • FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20230121325
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Application
    Filed: December 12, 2022
    Publication date: April 20, 2023
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Thomas MEIJER, Victor SÖDERBERG
  • Fast dissolving pharmaceutical compositions
    Patent number: 11529351
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: December 20, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Thomas Meijer, Victor Söderberg
  • Pharmaceutical compositions
    Patent number: 11517562
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: December 6, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220296575
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: June 1, 2022
    Publication date: September 22, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Pharmaceutical compositions
    Patent number: 11426391
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: August 30, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORMS CONTAINING DASATINIB
    Publication number: 20220257519
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 18, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Per ANDERSSON, Thomas MEIJER, Victor SÖDERBERG
  • FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220233532
    Abstract: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 28, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Thomas MEIJER, Victor SÖDERBERG
  • Pharmaceutical compositions
    Patent number: 11376243
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: July 5, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220168285
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 2, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Rapidly disintegrating solid oral dosage forms containing dasatinib
    Patent number: 11344500
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: May 31, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Per Andersson, Thomas Meijer, Victor Söderberg
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220160687
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: February 14, 2022
    Publication date: May 26, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220117947
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 21, 2022
    Applicant: XSPRAY PHARMA AB
    Inventors: Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
  • Pharmaceutical compositions
    Patent number: 11241419
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: February 8, 2022
    Assignee: XSPRAY PHARMA AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORMS CONTAINING DASATINIB
    Publication number: 20210085609
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Application
    Filed: December 2, 2020
    Publication date: March 25, 2021
    Applicant: XSPRAY PHARMA AB
    Inventors: Per ANDERSSON, Thomas MEIJER, Victor SÖDERBERG
  • Rapidly disintegrating solid oral dosage forms containing dasatinib
    Patent number: 10894018
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: January 19, 2021
    Assignee: XSPRAY PHARMA AB
    Inventors: Per Andersson, Thomas Meijer, Victor Söderberg
  • Rapidly disintegrating solid oral dosage forms containing dasatinib
    Patent number: 10894017
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: January 19, 2021
    Assignee: XSPRAY PHARMA AB
    Inventors: Per Andersson, Thomas Meijer, Victor Söderberg
  • Rapidly disintegrating solid oral dosage forms containing dasatinib
    Patent number: 10874614
    Abstract: The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: December 29, 2020
    Assignee: XSPRAY PHARMA AB
    Inventors: Per Andersson, Thomas Meijer, Victor Söderberg